COLON ERDERLY LOW DOSE

Launched by MATTEO CLAVAREZZA · Feb 18, 2025

Keywords

ClinConnect Summary

The COLON ERDERLY LOW DOSE trial is studying a specific treatment approach for older adults (70 years and older) with advanced colon cancer, known as metastatic colorectal adenocarcinoma. The researchers are looking at how effective a combination of lower-dose chemotherapy and a full-dose antibody treatment can be for these patients. The trial aims to gather information from patients who have not yet received treatment for their cancer at this advanced stage.

To be eligible for this study, patients need to be at least 70 years old and have a specific type of colon cancer that has not been treated while it was advanced. They should also have a certain score that indicates they can handle treatment. Patients with specific mutations in their cancer or those who are not suitable for a certain type of chemotherapy will not be included. If someone participates, they can expect to share their treatment experiences, which will help researchers understand the best ways to treat older adults with this type of cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted.
• • 2. Age ≥ 70 years
• • 3. G8 score ≥ 12
• • 4. Patients with colorectal adenocarcinoma MSS
• • 5. Patients with BRAF WT colorectal adenocarcinoma
• • 6. Ability to understand and sign the informed consent form.
• Exclusion Criteria:
• • 1. Patients with MSI tumours
• • 2. Patients with BRAF V600E mutated tumours
• • 3. Patients not eligible for doublet chemotherapy by clinical decision